Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: hoyasaxa who wrote (19789)	10/7/2004 4:10:24 PM
From: Bob Rudd	Read Replies (2) \| Respond to of 78614

I added PFE today @29 bringing my cost on entire position down to a bit over 30. A lot of the hand-wringing is over whether Celebrex which has shown no problems in shorter studies will evince risks in longer term studies as Vioxx did. This excerpt from a NYT piece reassures: "Pfizer issued a statement on friday saying that three trials involving a total of 6,000 patients that have been under way for several years had not shown any significant safety issues. The tests are trying to determine whether celebrex can help prevent colon cancer or prevent or slow alzheimer's disease." The concerns may benefit PFE by delaying MRK's Arcoxia from being released as scheduled...in any event, it's highly unlikely a new cox-2 from MRK would get any scripts. With the difficult to quantify litigation risk, I wouldn't consider MRK unless it was half the multiple of PFE.